TOP2A and non-small cell lung carcinoma: Our current findings suggest that TOP2A is involved in regulating the expression of immune checkpoint (PD-L1) in NSCLC, and the upregulation of TOP2A significantly promotes the expression of immune checkpoint (PD-L1).